DexCom (NASDAQ:DXCM) Sets New 52-Week Low – Should You Sell?

DexCom, Inc. (NASDAQ:DXCM)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $61.74 and last traded at $62.24, with a volume of 1724552 shares traded. The stock had previously closed at $68.14.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DXCM. Canaccord Genuity Group raised their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Cfra Research upgraded shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Down 9.3 %

The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a 50-day moving average of $81.24 and a two-hundred day moving average of $77.04. The company has a market cap of $24.15 billion, a P/E ratio of 43.22, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last three months. 0.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Townsquare Capital LLC increased its position in shares of DexCom by 43.6% during the third quarter. Townsquare Capital LLC now owns 9,568 shares of the medical device company’s stock valued at $641,000 after buying an additional 2,905 shares during the period. Public Sector Pension Investment Board raised its position in shares of DexCom by 5.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 17,842 shares of the medical device company’s stock worth $1,196,000 after acquiring an additional 1,000 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of DexCom by 4.6% in the 3rd quarter. Captrust Financial Advisors now owns 23,051 shares of the medical device company’s stock valued at $1,545,000 after purchasing an additional 1,022 shares during the period. Erste Asset Management GmbH bought a new stake in shares of DexCom during the third quarter valued at approximately $694,000. Finally, Benjamin Edwards Inc. purchased a new stake in DexCom in the third quarter worth $652,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.